International Plastic Bronchitis Registry
The purpose of the international plastic bronchitis registry is to understand the natural course and long term health outcomes of subjects diagnosed with plastic bronchitis due to different types of casts. This provides essential data for identifying best practices and treatments. The secondary aim is to understand the structure of casts and mechanism of their formation.
|Study Design:||Observational Model: Cohort
Time Perspective: Prospective
|Official Title:||International Plastic Bronchitis Registry|
- natural course and long term health outcomes [ Time Frame: ongoing ] [ Designated as safety issue: No ]The purpose of the intrnational plastic bronchitis registry is to understand the natural course and long term health outcomes of patients diagnosed with plastic bronchitis. This provides essential data for identifying possible causes of this disease and potential treatments.
Biospecimen Retention: Samples With DNA
|Study Start Date:||July 2012|
|Estimated Study Completion Date:||July 2022|
|Estimated Primary Completion Date:||July 2022 (Final data collection date for primary outcome measure)|
|Patients with Plastic bronchitis|
Plastic bronchitis (PB) patients have casts removed during bronchoscopy as part of their routine care or that they are able to expectorate (cough out) casts naturally. The casts are normally discarded. Patients that agree to participate in the registry ship the airway casts and medical history to Dr. Bruce Rubin's Research Laboratory at Virginia Commonwealth University Richmond Virginia, USA.
The lab evaluates the biopolymer composition and structure of the airway casts by immunohistochemistry in order to identify microscopic differences between expectorated casts of subjects with plastic bronchitis and sputum from other populations (cystic fibrosis,chronic obstructive pulmonary disease , and normal airways). The lab also conducts in vitro evaluation of clearability, adhesivity, cohesivity, and inflammatory mediator concentrations to better understand the nature of the disease.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01663948
|Contact: Jennifer L Bradley, B.Afirstname.lastname@example.org|
|United States, Virginia|
|Virginia Commonwealth University||Recruiting|
|Richmond, Virginia, United States, 23298|
|Contact: Jennifer L Bradley, B.A 8046282793 email@example.com|
|Principal Investigator: Bruce k Rubin, MEngr, MD, MBA, FRCPC|
|Principal Investigator:||Bruce K Rubin, MEngr, MD, MBA, FRCPC||Children's Hospital of Richmond at VCU|